Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review
BJPsych Open2018Vol. 4(4), pp. 215–225
Citations Over TimeTop 10% of 2018 papers
Andrew Thompson, Catherine Winsper, Steven Marwaha, Jon Haynes, Mario Álvarez‐Jiménez, Sarah Hetrick, Alba Realpe, Laura Vail, Sarah Dawson, Sarah Sullivan
Abstract
A.T. has received honoraria and support from Janssen-Cilag and Otsuka Pharmaceuticals for meetings and has been has been an investigator on unrestricted investigator-initiated trials funded by AstraZeneca and Janssen-Cilag. He has also previously held a Pfizer Neurosciences Research Grant. S.M. has received sponsorship from Otsuka and Lundbeck to attend an academic congress and owns shares in GlaxoSmithKline and AstraZeneca. J.H. has attended meetings supported by Sunovion Pharmaceuticals.
Related Papers
- → Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery?(2013)106 cited
- → Research in Schizophrenia and the Discontinuation of Antipsychotic Medications(1997)52 cited
- → First-episode schizophrenia(1998)80 cited
- → Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how?(2017)4 cited
- → The Influence of Unmeasured Confounding Effects in a Study of Antipsychotic Discontinuation in First-Episode Schizophrenia(2018)